|1.||Searle, P F: 9 articles (03/2008 - 01/2000)|
|2.||Young, L S: 7 articles (01/2008 - 05/2000)|
|3.||Kerr, D J: 7 articles (08/2005 - 05/2000)|
|4.||Searle, Peter F: 6 articles (01/2010 - 09/2003)|
|5.||Kerr, David J: 4 articles (07/2010 - 01/2003)|
|6.||Hyde, Eva I: 4 articles (01/2010 - 09/2003)|
|7.||Grove, Jane I: 4 articles (01/2010 - 09/2003)|
|8.||Knox, Richard J: 4 articles (01/2010 - 01/2003)|
|9.||Mautner, Vivien: 4 articles (11/2009 - 05/2004)|
|10.||Mautner, V: 4 articles (01/2008 - 01/2000)|
02/01/2004 - "The introduction of suicide genes incorporating the bacterial enzyme nitroreductase gene (ntr) targeted at tumor cells prior to administration of the prodrug CB-1954, converted by ntr into a toxic alkylating agent, was discussed against the background of clinical trials and improved suicide gene design. "
01/01/2009 - "The nitroreductase/5-(azaridin-1-yl)-2,4-dinitrobenzamide (NTR/CB1954) enzyme/prodrug system is considered as a promising candidate for anti-cancer strategies by gene-directed enzyme prodrug therapy (GDEPT) and has recently entered clinical trials. "
04/27/2007 - "NTR in combination with CB1954 has entered clinical trials for virus-directed enzyme-prodrug therapy of cancer. "
08/01/2005 - "Virus-directed enzyme prodrug therapy utilizing the bacterial enzyme nitroreductase delivered by a replication-defective adenovirus vector to activate the prodrug CB1954 is a promising strategy currently undergoing clinical trials in patients with a range of cancers. "
11/01/2004 - "3. A phase I trial of CB1954 in cancer patients has been completed, documenting the pharmacokinetics and establishing an acceptable dose. "
|2.||Prostatic Neoplasms (Prostate Cancer)
01/01/2008 - "The nitroreductase (NR)/CB1954 enzyme prodrug system has given promising results in pre-clinical studies and is currently being assessed in phase I and II clinical trials in prostate cancer. "
11/01/2009 - "We have completed a phase I/II suicide gene therapy clinical trial in patients with prostate cancer, using an E1/E3-deleted replication-deficient adenovirus (CTL102) encoding the bacterial nitroreductase enzyme in combination with prodrug CB1954. "
07/01/2009 - "We report a phase I/II clinical trial in prostate cancer (PCa) using direct intraprostatic injection of a replication defective adenovirus vector (CTL102) encoding bacterial nitroreductase (NTR) in conjunction with systemic prodrug CB1954. "
07/01/2009 - "A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]."
|3.||Colorectal Neoplasms (Colorectal Cancer)
07/01/2004 - "The combination of viral oncolysis and NTR expression results in significantly greater sensitization of SW480 and WiDr colorectal cancer cells to the prodrug CB1954 in vitro. "
12/01/2005 - "Both viruses express NTR in colorectal cancer cell lines and show increased cytopathic effect in the presence of the prodrug CB1954. "
|4.||Burkitt Lymphoma (Burkitt's Lymphoma)
09/15/2012 - "In a bacteria-delivered model for enzyme prodrug therapy, the engineered FRase I variants were able to kill human colon carcinoma (HCT-116) cells at significantly lower CB1954 concentrations than wild type FRase I or E. "
03/01/2010 - "NfsA also confers sensitivity to CB1954 when expressed in HCT-116 human colon carcinoma cells, with similar efficiency to NfsB. "
04/01/2007 - "Carcinoma cells infected with adenovirus expressing T41Q/N71S/F124T-NTR were sensitized to CB1954 concentrations 40- to 80-fold lower than required with WT-NTR."
09/01/2003 - "Using an adenovirus vector, we introduced the F124K NTR mutant into human SK-OV-3 ovarian carcinoma cells and showed it to be approximately 5-fold more potent in sensitizing the cells to CB1954 at the clinically relevant prodrug concentration of 1 micro M than was the WT enzyme. "
06/15/2000 - "Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. "
|7.||DNA (Deoxyribonucleic Acid)
|8.||NAD(P)H Dehydrogenase (Quinone) (Quinone Reductase)
|9.||NRH - quinone oxidoreductase2
|1.||Heterologous Transplantation (Xenotransplantation)